CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance

CNS Pharmaceuticals, Inc.

Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.
O'Loughlin receives initial RSU grant of 9,500 shares; 25% vest at 6 months, 25% at 12 months, 50% quarterly thereafter.
Current CFO Christopher Downs resigns as CFO, becomes SVP - Finance effective March 2; base salary $350,000, target bonus 30%.
Both employment agreements include 6-month severance (base salary) for termination without cause or for good reason.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.